Agents and Methods for the Prevention or Treatment of H. Pylori Infections

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes new agents and methods for the prevention or treatment of infections caused by Helicobacter pylori (H. pylori), a common stomach bacterium linked to ulcers and gastric cancer. The core invention is focused on inhibiting the binding between a bacterial protein called HopQ and human cell surface proteins (CEACAM family), which are critical for H. pylori to establish infection and cause disease. The invention proposes various molecules—such as antibodies, peptides, nucleic acids, and small molecules—that prevent this interaction, as well as immunogenic compositions (like vaccines) targeting HopQ to elicit a protective immune response.

Use CasesContent extracted from patent full text and abstract with AI.

• Prevention and treatment of H. pylori infection using therapeutic agents that block HopQ-CEACAM binding.
• Development of vaccines against H. pylori by targeting the HopQ protein to elicit an immune response.
• Use of HopQ-CEACAM inhibitors as adjunct or alternative therapy to antibiotics in cases of antibiotic-resistant H. pylori.
• Screening or development of new drugs for gastric diseases associated with H. pylori.
• Prophylactic treatment in high-risk populations for gastric cancer and ulcers caused by H. pylori.
• Laboratory tools (e.g., in vitro assays, animal models) for studying H. pylori infection and drug discovery.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel, non-antibiotic approach to the prevention and treatment of H. pylori, which helps address the growing problem of antibiotic resistance.
• Targets a specific bacterial-host interaction, potentially reducing side effects compared to broad-spectrum antibiotics.
• May prevent not only infection but also severe complications such as ulcers, gastric cancer, and MALT lymphoma.
• Supports the development of effective vaccines against H. pylori, a long-sought goal in infectious disease.
• Reduces health care costs associated with chronic gastric diseases and cancer by offering effective preventive strategies.
• Can be adapted into multiple therapeutic formats (antibodies, peptides, nucleic acids, small molecules, vaccines), providing flexibility for clinical use.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.